Approximately 20% of breast cancers harbor human epidermal growth factor receptor 2 (HER2/ERBB2) overexpression or amplification. KN026, a novel HER2 bispecific antibody, has been shown to overcome resistance to HER2 target therapies in preclinical models. Zhang and colleagues conducted a phase I trial of KN026 in patients with HER2-positive metastatic breast cancer who had progressed on prior anti-HER2 therapies. KN026 was well tolerated, and treatment led to an objective response rate of 28.1%. Furthermore, the authors associated CDK12 co-amplification with an improved response to KN026, supporting further assessment of this potential biomarker. Although these results are interesting, further clinical trials of this novel bispecific antibody are warranted.

Metastasis is a common occurrence in patients with osteosarcoma. Although current therapeutics have shown limited ability to reduce metastasis, CCR2+ monocytes have emerged as an actionable target for the prevention of lung metastasis. Regan and colleagues conducted a clinical trial in pet dogs...

You do not currently have access to this content.